Smoking is Associated with COVID-19 Progression: A Meta-Analysis

Roengrudee Patanavanich[1, 2] MD LLM PhD
Stanton A. Glantz[1] PhD

[1]Center for Tobacco Control Research and Education
Department of Medicine
University of California San Francisco
San Francisco, CA, U.S.A. 94143-1390
[2]Department of Community Medicine
Faculty of Medicine Ramathibodi Hospital
Mahidol University, Thailand

Corresponding author:
Stanton Glantz, PhD
Center for Tobacco Control Research and Education
530 Parnassus Avenue, Suite 366
University of California, San Francisco
San Francisco, CA, U.S.A. 94143-1390
415-476-3893
Stanton.Glantz@ucsf.edu

INTRODUCTION

COVID-19, the coronavirus-transmitted infectious disease, has caused a worldwide pandemic. Smoking[1,2] and e-cigarette use[3] increases risk and severity of pulmonary infections because of damage to upper airways and a decrease in pulmonary immune function. In particular, smokers have a higher risk of infection and mortality from Cov-MERS.[4] Two reviews[5,6] of the first 5 papers presenting data on smoking and COVID-19 reached different conclusions. Another review described 6 published case series presenting data on smoking among COVID-19 patients but did not draw a conclusion about the association of severity of COVID-19 with smoking.[7] We reviewed and summarized 19 peer-reviewed papers presenting data on the association between smoking and severity of COVID-19.

METHODS

We conducted a systematic search using PubMed on April 28, 2020, with the search term: ((smoking) OR (characteristics) OR (risk factors) OR (outcomes) OR (smoker*)) AND ((COVID-19) OR (COVID) OR (coronavirus) OR (sars cov-2) OR (sars cov 2)) for studies published between January 1, 2020 and April 28, 2020. One author extracted information for each study, screened the abstract or the full text, with questions resolved through discussion among both authors. There were no language restrictions. A total of 907 studies were retrieved through the search, of which 19,[8-26] 16 from China, 1 from Korea, and 2 from the U.S., included data on smoking behavior and COVID-19 disease progression (Table S1). Seventeen studies[9-12,14-26] were based on hospitalized patients and two[8,13] included both hospitalized patients and outpatients.

The exposure group for our analysis were those who had a history of smoking (current smokers or former smokers) and unexposed group was never smokers. Nine studies[10,12,14,18,20,21,23,25,26] assessed whether the patient was a "current smoker," five studies[8,9,13,16,24] assessed whether the patient was a current or former smoker (as separate

2

categories), and five studies[11,15,17,19,22] assessed whether the patient had a "history of smoking" (current or former).

Outcomes were progression of COVID-19 to more severe or critical conditions or death. Six studies[11,16,20,21,23,24] categorized the outcome as severe or critical (respiratory distress with respiratory rate ≥ 30/min, or oxygen saturation ≤ 93% at rest, or oxygenation index ≤ 300 mmHg, based on the diagnostic and treatment guideline for SARS-CoV-2 issued by Chinese National Health Committee or the American Thoracic Society guidelines for community acquired pneumonia[23,24]) or non-severe, three[10,17,18] categorized the outcome as progression or improvement, two[8,14] categorized the outcome as ICU admission or non-ICU admission, one[13] categorized the outcome as the primary composite end point (ICU admission, the use of mechanical ventilation, or death) or not, three[9,22,26] categorized the outcome as death or survivor, one[19] categorized the outcome as the occurrence of severe cases (without defining severe) or death or mild, one study[15] categorized the outcome as clinical deterioration during the hospitalization and needed supplemental oxygen therapy, one[12] categorized the outcome as a need of intensive mechanical ventilators, and one[25] categorized the outcome as abnormal chest imaging findings.

We also conducted sensitivity analysis using the 5 studies[8,9,13,16,24] that we were able to compare the association of severity of COVID-19 between current smokers and never smokers.

We computed unadjusted odds ratios (OR) and 95% confidence interval (CI) for each study using the number of smokers (current and former) and never smokers with and without disease progression. Random effects meta-analysis was performed using the Stata version 14.0 *metan* command and using *metabias* command with Harbord and Peters to test for the presence of publication bias.

3

RESULTS

A total of 11,590 COVID-19 patients included in our meta-analysis, 2,133 of whom (18.4%) experienced disease progression and 731 (6.3%) with a history of smoking. A total of 218 patients with a history of smoking (29.8%) experienced disease progression, compared with 17.6% of non-smoking patients. The meta-analysis showed an association between smoking and COVID-19 progression (OR 1.91, 95% CI 1.42-2.59, p=0.001) (Figure 1). There was moderate heterogeneity among the studies (I^2=38%, *p*=0.048) and no significant evidence of publication bias (Harbord's *p*=0.813, Peters' *p*=0.941).

Sensitivity analysis of the five studies[8,9,13,16,24] of current smokers vs. never smokers yielded a similar result (OR 1.91, 95% CI 1.10-3.29, p=0.021). There was no evidence of significant heterogeneity (I^2=53.5%, *p*=0.072) or publication bias (Harbord's *p*=0.382, Peters' *p*=0.512) among the studies.

DISCUSSION

Our analysis confirms that smoking is a risk factor for progression of COVID-19, with smokers having 1.91-times the odds of progression in COVID-19 severity than never smokers. This finding contrasts with an earlier meta-analysis,[6] which included only 5 studies and used a non-standard method to compute the meta-analysis. The finding that smoking is associated with COVID-19 progression is not surprising because of the adverse effects of smoking on pulmonary immune function.[1,2]

Some [27,28] have argued that the fact that reported smoking prevalence in COVID patients is lower than has been reported in the general population as evidence for a protective effect of smoking. As noted above, the low prevalence reported among COVID patients may be due to under-assessment of smoking, especially in the difficult conditions present when caring for people in overwhelmed health systems.[29,30] In any event, our analysis shows that

4

among those people assessed as smokers risk of disease progression is significantly

increased.

Limitations

Our study has several limitations.

The definition of "smoking" sometimes includes former smokers and sometimes does

not. Only three studies[8,13,24] separated current and former smokers in different categories,

which was not enough data to do a meta-analysis for current and former smokers separately.

Because the lung recovers after someone stops smoking, including former smokers in the

exposed group may bias the effect estimate to the null. Reported smoking prevalence in the

16 studies in China ranged from 3.7% to 16.8%, which was substantially lower than 27.7%

(52.1% for men and 2.7% for women) smoking prevalence in 2015.[31] Reported smoking

prevalence in the U.S. (3.6-5.1%) and Korea (18.5%) studies were also lower than the

countries' smoking prevalence; U.S. smoking prevalence in 2018 was 13.7% (15.6% for men

and 12.0% for women)[32] and Korea in 2017 was 21.1% (37.0% for men and 5.2% for

women).[33] It is highly likely that many smokers were misclassified as nonsmokers, which

would bias the risk estimate toward the null.

This analysis is based on unadjusted ORs that were either reported in the studies[17] or

that we calculated based on counts in the studies.[8-16,18-26] Only one[17] of the studies reported

unadjusted and adjusted ORs using multivariate analysis; after adjusting for confounding by

age, maximum temperature at admission, respiratory failure, severe illness, albumin,

creatinine, procalcitonin, and C-reactive protein level, the effect of smoking on disease

severity increased (unadjusted: OR 12.19, 95% CI 1.76-84.31, p=0.011; adjusted: OR 14.29,

95% CI 1.58-25.0, p=0.018). Three peer-reviewed meta-analysis papers[6,34,35] on association

between smoking and COVID-19 were also based on unadjusted odds ratios, but with fewer

studies included.

5

None of these studies assessed e-cigarette use.

All these limitations suggest that this analysis underestimates the risk of smoking in terms of increasing COVID-19 severity.

All 19 studies were of patients who had already developed COVID-19, so the risk estimate we report does not represent the effect of smoking on the risk of contracting COVID-19 in the general population. As population-level testing ramps up, it would be useful to collect data on smoking and e-cigarette use to determine what risks these behaviors impose in terms of infection.

Conclusions

Smoking is associated with COVID-19 disease progression. Physicians and public health professionals should collect data on smoking and, given the pulmonary effects of e-cigarettes,[3] e-cigarette use as part of clinical assessments and add smoking (and, to be health protective, e-cigarette) cessation to the list of practices to blunt the COVID-19 pandemic.

COMPETITING INTERESTS

Nothing to report.

CONTRIBUTORSHIP

RP developed the idea for the study, collected, analyzed the data, and wrote the first

draft of the manuscript. SAG assisted with revising and refining the manuscript.

DATA SHARING STATEMENT

All data used to prepare this paper are available from the cited sources.

DISCLOSURE

The authors have nothing to disclose.

REFERENCES

1.   Arcavi L, Benowitz NL. Cigarette smoking and infection. *Arch Intern Med.*
      2004;164(20):2206-2216. .doi: 10.1001/archinte.164.20.2206 [published Online First:
      2004/11/10].

2.   Bauer CMT, Morissette MC, Stämpfli MR. The Influence of Cigarette Smoking on
      Viral Infections: Translating Bench Science to Impact COPD Pathogenesis and Acute
      Exacerbations of COPD Clinically. *Chest.* 2013;143(1):196-206. .doi:
      https://doi.org/10.1378/chest.12-0930

3.   Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e-
      cigarettes? *BMJ.* 2019;366:l5275. .doi: 10.1136/bmj.l5275 [published Online First:
      2019/10/02].

4.   Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic
      review. *BMC Public Health.* 2018;18(1):574. .doi: 10.1186/s12889-018-5484-8
      [published Online First: 2018/05/03].

5.   Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the
      evidence. *Tob Induc Dis.* 2020;18:20 doi: 10.18332/tid/119324 [published Online
      First: 2020/03/25].

6.   Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus
      disease 2019 (COVID-19). *Eur J Intern Med.* 2020.doi: 10.1016/j.ejim.2020.03.014
      [published Online First: 2020/03/21].

7.   Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and smoking. *Nicotine Tob
      Res.* 2020.doi: 10.1093/ntr/ntaa059 [published Online First: 2020/04/04].

8.   CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of
      Selected Underlying Health Conditions Among Patients with Coronavirus Disease
      2019 - United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep.*

2020;69(13):382-386. doi: 310.15585/mmwr.mm16913e15582.doi:

10.15585/mmwr.mm6913e2 [published Online First: 2020/04/03].

9.   Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with

coronavirus disease 2019: retrospective study. *BMJ.* 2020;368:m1091.doi:

10.1136/bmj.m1091

10.   Dong X, Cao YY, Lu XX, et al. Eleven Faces of Coronavirus Disease 2019. *Allergy.*

2020.doi: 10.1111/all.14289 [published Online First: 2020/03/21].

11.   Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severity: A Multi-center

Study of Clinical Features. *Am J Respir Crit Care Med.* 2020.doi:

10.1164/rccm.202002-0445OC [published Online First: 2020/04/11].

12.   Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New

York City. *N Engl J Med.* 2020.doi: 10.1056/NEJMc2010419 [published Online First:

2020/04/18].

13.   Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in

China. *N Engl J Med.* 2020.doi: 10.1056/NEJMoa2002032 [published Online First:

2020/02/29].

14.   Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel

coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506. .doi:

10.1016/s0140-6736(20)30183-5 [published Online First: 2020/01/28].

15.   Kim ES, Chin BS, Kang CK, et al. Clinical Course and Outcomes of Patients with

Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of

the First 28 Patients from the Korean Cohort Study on COVID-19. *J Korean Med Sci.*

2020;35(13):e142 doi: 10.3346/jkms.2020.35.e142 [published Online First:

2020/04/04].

16. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020.doi: 10.1016/j.jaci.2020.04.006 [published Online First: 2020/04/16].

17. Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl).* 2020.doi: 10.1097/cm9.0000000000000775 [published Online First: 2020/03/03].

18. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis.* 2020.doi: 10.1093/cid/ciaa270 [published Online First: 2020/03/17].

19. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care.* 2020;24(1):108. .doi: 10.1186/s13054-020-2833-7 [published Online First: 2020/03/20].

20. Wan S, Xiang Y, Fang W, et al. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. *J Med Virol.* 2020.doi: 10.1002/jmv.25783 [published Online First: 2020/03/22].

21. Wang R, Pan M, Zhang X, et al. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. *Int J Infect Dis.* 2020.doi: 10.1016/j.ijid.2020.03.070 [published Online First: 2020/04/15].

22. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* 2020.doi: 10.1016/s2213-2600(20)30079-5 [published Online First: 2020/02/28].

23.   Yao Q, Wang P, Wang X, et al. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. *Pol Arch Intern Med.* 2020.doi: 10.20452/pamw.15312 [published Online First: 2020/04/25].

24.   Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy.* 2020.doi: 10.1111/all.14238 [published Online First: 2020/02/23].

25.   Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. *Int J Infect Dis.* 2020;94:81-87.doi: 10.1016/j.ijid.2020.03.040 [published Online First: 2020/03/25].

26.   Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020.doi: 10.1016/s0140-6736(20)30566-3 [published Online First: 2020/03/15].

27.   Fontanet A, Tondeur L, Madec Y, et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study. *medRxiv.* 2020:2020.2004.2018.20071134.doi: 10.1101/2020.04.18.20071134

28.   Miyara M, Tubach F, Pourcher V, et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. *Qeios.* 2020.doi: 10.32388/wpp19w.3

29.   Polubriaginof F, Salmasian H, Albert DA, Vawdrey DK. Challenges with Collecting Smoking Status in Electronic Health Records. *AMIA Annu Symp Proc.* 2018;2017:1392-1400. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977725/.

30.   Schofield PE, Hill DJ. How accurate is in-patient smoking status data collected by hospital admissions staff? *Aust N Z J Public Health.* 1999;23(6):654-656.doi: 10.1111/j.1467-842x.1999.tb01555.x [published Online First: 2000/01/21].

11

31. Parascandola M, Xiao L. Tobacco and the lung cancer epidemic in China. *Translational Lung Cancer Research.* 2019:S21-S30. . http://tlcr.amegroups.com/article/view/28292.

32. Centers for Disease Control and Prevention. Current Cigarette Smoking Among Adults in the United States. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm. Published 2019. Accessed April 6, 2020.

33. World Health Organization. WHO report on the global tobacco epidemic, 2019: Country profile Republic of Korea. https://www.who.int/tobacco/surveillance/policy/country_profile/kor.pdf?ua=1. Published 2019. Accessed April 6, 2020.

34. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis. *Journal of Medical Virology.*n/a(n/a).doi: 10.1002/jmv.25889

35. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect.* 2020.doi: 10.1016/j.jinf.2020.04.021 [published Online First: 2020/04/27].

12

Smoking and COVID-19 Disease Progression

Study	OR (95% CI)	% Weight
CDC COVID-19 Response Team (US)	2.60 (1.82, 3.73)	14.49
Chen T, et al	1.31 (0.51, 3.33)	6.63
Dong X, et al.	1.15 (0.03, 38.88)	0.71
Feng Y, et al.	1.91 (1.00, 3.64)	9.95
Goyal P, et al (US)	0.86 (0.32, 2.29)	6.23
Guan WJ, et al.	3.25 (1.89, 5.59)	11.47
Huang C, et al.	0.27 (0.01, 5.62)	0.94
Kim ES, et al. (Korea)	3.17 (0.39, 25.58)	1.87
Li X, et al	1.38 (0.88, 2.17)	12.97
Liu W, et al.	12.19 (1.76, 84.31)	2.15
Mo P, et al.	1.68 (0.30, 9.45)	2.61
Shi Y, et al.	1.60 (0.64, 4.04)	6.74
Wan S, et al.	0.28 (0.03, 2.31)	1.83
Wang R, et al	3.93 (1.30, 11.93)	5.26
Yang X, et al.	0.11 (0.01, 2.50)	0.91
Yao Q, et al	11.18 (1.11, 112.83)	1.56
Zhang JJ, et al.	3.04 (0.73, 12.69)	3.58
Zhang X et al	1.17 (0.41, 3.39)	5.59
Zhou F, et al.	2.23 (0.65, 7.63)	4.52
Overall (I-squared = 38.0%, p = 0.048)	1.91 (1.42, 2.59)	100.00

NOTE: Weights are from random effects analysis

.1 .2 .5 1 2 5 10 20 50
Less severe   More severe

Figure 1. Smoking is associated with COVID-19 progression. All papers from China unless otherwise indicated.